Mesoblast Limited files as an Australian foreign private issuer, and its SEC reports document ASX announcements for its ADR-listed securities. Form 6-K reports incorporate Appendix 4C activity reports, press releases and R&D materials covering Ryoncil commercialization, operating cash spend, clinical programs for rexlemestrocel-L and Ryoncil, FDA regulatory updates and the company’s mesenchymal lineage cell therapy platform.
The filing record also documents capital-structure and governance matters through ASX appendices for proposed and quoted securities, unquoted equity securities, cessation of securities and changes in director interests. These disclosures connect Mesoblast’s public reporting to product revenue, pipeline development, equity issuance and foreign-issuer compliance under Form 20-F reporting.
Mesoblast Limited reported strong progress for the quarter ended March 31, 2026. Lead product Ryoncil® generated gross sales of US$35.3 million and net revenues of US$30.3 million, with first-year launch revenues approaching US$100 million. Net operating cash spend was reduced to US$4.1 million, supported by customer receipts of US$34.6 million and tight cost control.
The company ended the quarter with US$121.8 million in cash and cash equivalents and reported total available funding of US$171.8 million, equivalent to an estimated 41.8 quarters of funding at the current cash burn rate. Mesoblast achieved its patient recruitment target in a pivotal phase 3 trial of rexlemestrocel‑L for chronic low back pain and received FDA clearance to begin a label‑extension trial of Ryoncil in adults with steroid‑refractory acute graft versus host disease, as well as IND clearance for a registrational trial in Duchenne muscular dystrophy. The company also acquired an exclusive worldwide license to a patented CAR technology platform to develop next‑generation mesenchymal stromal cell products for inflammatory and autoimmune diseases.
Mesoblast Ltd director Lynette Elizabeth Cobley filed an initial Form 3 showing her existing equity stake. She reports 30,000 Ordinary Shares held directly and 33,000 Ordinary Shares held indirectly through Synergy Finance Pty Ltd as trustee for her self-managed superannuation fund. She also holds an option over 200,000 Ordinary Shares at an exercise price of $1.72 per share, expiring on May 9, 2032. According to the footnote, these options were granted on May 10, 2025 and vest in three annual tranches through 2028.
Mesoblast Limited reported that its pivotal Phase 3 trial of rexlemestrocel-L for chronic low back pain associated with degenerative disc disease has reached its patient recruitment target of at least 300 participants. Patients receive a single intra-discal injection of rexlemestrocel-L or sham control and are followed for 12 months.
The study aims to confirm earlier Phase 3 results that showed clinically meaningful pain and opioid-use reductions for up to three years. Top-line data are expected in mid-CY2027, with a planned U.S. FDA Biologics License Application filing in Q3 CY2027. Rexlemestrocel-L holds Regenerative Medicine Advanced Therapy designation, and Mesoblast sees potential peak year revenue above US$10 billion at single-digit market penetration, given over 7 million affected patients in the U.S.
Mesoblast Limited furnished a Form 6-K that forwards several Australian Securities Exchange appendices on new equity issues and changes in securities, including a detailed change of director’s interest notice for Gregory George.
The notice shows an increase in his indirect holdings after on-market purchases by related holders. These trades added 70,000 American Depositary Shares (ADS), with each ADS representing 10 ordinary shares, and 7,210,962 ordinary shares. The filing states total cash consideration of US$11,429,969.84 for the ADS and ordinary shares purchased. Following the transactions, his indirect interests rose to 12,855,154 ordinary shares, 14,485,410 ADS, and 6,830,602 warrants to acquire ordinary shares, while his direct positions were unchanged.
Mesoblast Ltd director and ten percent owner George Gregory reported a series of indirect open-market purchases of Ordinary Shares. Between April 4 and April 10, related accounts for Grant George and James George, each granting power of attorney to Dr. George, bought a combined 7,910,962 Ordinary Shares at prices between $1.41 and $1.48 per share. The filing shows indirect holdings in these accounts increasing to as many as 13,586,890 Ordinary Shares following the transactions. A footnote explains that these Ordinary Shares are represented by American Depositary Shares, with each ADS reflecting a beneficial interest in 10 Ordinary Shares, and that reported prices are already adjusted to the per‑Ordinary‑Share level.
Mesoblast Ltd director and 10% owner George Gregory, through accounts held by Grant George and James George over which he has power of attorney, reported open-market purchases totalling 8,305,962 Ordinary Shares of Mesoblast.
Individual transactions on April 4, April 9 and April 10, 2026 ranged from 4,000,000 shares at $1.42 per share to smaller blocks around $14.10–$14.40 per share. Following these purchases, the reported indirect holdings in the various accounts increased, with the largest shown position reaching 13,586,890 Ordinary Shares. The Ordinary Shares are represented by American Depositary Shares, with each ADS corresponding to a beneficial interest in 10 Ordinary Shares.
Mesoblast Limited used its R&D Day to highlight rapid commercial progress with Ryoncil and a late‑stage pipeline targeting multi‑billion‑dollar inflammatory indications. Ryoncil net revenue is approaching US$100 million since its U.S. launch last year, with Q3 FY26 gross revenue of US$35 million and net revenue of US$30 million.
The company reported H1 FY26 Ryoncil gross profit of US$44 million against US$7 million in direct selling costs, and a cash balance of US$130 million at December 31 2025, supported by a new US$125 million term loan. Management targets FY26 net revenue of US$110–120 million and aims to double Ryoncil revenue.
Mesoblast is advancing Phase 3 programs for chronic low back pain and inflammatory heart failure, each with stated total addressable markets above US$10 billion, plus label extensions for Ryoncil in adult SR‑aGvHD and Duchenne muscular dystrophy. Next‑generation CAR‑ and oncolytic virus‑engineered MSC platforms and manufacturing upgrades are intended to support long‑term growth.
Mesoblast Limited reports that the U.S. FDA has granted Investigational New Drug (IND) clearance to proceed directly to a registrational clinical trial of Ryoncil (remestemcel-L-rknd) in Duchenne muscular dystrophy (DMD), a disease affecting about 15,000 children in the U.S.
The randomized trial will enroll 76 children aged 5 to 9 years to receive either Ryoncil or placebo on top of standard care, with seven infusions over nine months. The primary endpoint will be time-to-stand at nine months, an FDA-validated measure for approval.
Ryoncil, already FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients, is being studied for its anti-inflammatory effects in DMD. Mesoblast is partnering with Parent Project Muscular Dystrophy to support patient identification and trial awareness.
Mesoblast Limited reports that Ryoncil® (remestemcel-L-rknd) generated net sales of US$30.3 million for the quarter ended March 31, 2026, marking a strong finish to Ryoncil’s first year on the market. February and March sales offset weaker, holiday-affected demand in January, and total Ryoncil® revenue since launch now approaches US$100 million, helping to strengthen the company’s balance sheet and fund label extension and late-stage programs.
Ryoncil® is described as the first mesenchymal stromal cell therapy approved by the U.S. FDA for any indication and the only FDA-approved treatment for children under 12 with steroid-refractory acute graft-versus-host disease. Mesoblast will present its Ryoncil® growth strategy and late-stage pipeline at an inaugural R&D Day in New York on April 8, 2026, alongside updates on its broader allogeneic cell therapy portfolio.
Mesoblast Limited submitted a Form 6-K as a foreign private issuer to provide U.S. investors with access to two Australian Securities Exchange filings. The report furnishes an April 7, 2026 Appendix 3B new issue announcement and an April 8, 2026 Appendix 2A application for quotation of securities as exhibits.